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Issues with data analysis have recently been highlighted 
by a reader of our article. These have been addressed with 
changes to Tables 2 and 4, as shown below, and Online 
Resources 5–7. T2 and peritumoral signal are no longer 
prognostic factors on simple pooled (Online Resource 5) and 
IPD (Table 4) analyses respectively. In Table 5, the number 
of patients which informed the outcomes symptom devel-
opment and intervention were 575 and 947 respectively; 
69 developed symptoms (pooled proportion %8.4 [95% CI 
2.8–16.7],  I2 = 88.9%). These included motor and cognitive 
deficits (n = 1). We apologise to the readership of the Journal 
of Neuro-Oncology for these errors and thank the reader for 
helping us identify them.
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Table 2  Baseline clinical and radiological characteristics
NR not reported, SRS stereotactic radiosurgery
a One study which dichotomized location into supratentorial and infratentorial was excluded [15]
b Available in one study which did not report SD [25]
No. of studies 
informing char-
acteristic
No. of valid 
cases informing 
characteristic (%)
Characteristics Total Surgery SRS Active monitor-
ing
P
18 2050 N. of patients (%) 2050 560 (27.3) 450 (22.0) 1040 (50.7)
13 803 (39.2) Mean age, years 
(SD)
63.1 (6.9) 61.5 (4.7) 54.9 (NR)b 64 (6.9) < 0.001
17 1948 (95.0) Sex, N (%) Female 1549 369 (23.8) 363 (23.4) 817 (52.7) 0.539
Male 399 89 (22.3) 87 (21.8) 223 (55.9)
16 1495 (72.9) Location, N (%)a Non-skull base 1024 277 (27.1) 235 (22.9) 512 (50.0) < 0.001
Convexity 431 126 86 219
Parafalcine 245 61 71 113
Parasagittal 151 42 36 73
Tentorial 62 12 28 22
Intraventricular 26 4 12 10
Skull base 471 106 (22.5) 154 (32.7) 211 (44.8)
Anterior midline 112 22 43 47
Sphenoid wing 98 25 11 62
Posterior fossa 
- lateral and 
posterior
52 23 12 17
Posterior fossa - 
midline
138 17 87 34
15 888 (43.3) Mean diameter, 
cm (SD)
2.14 (0.61) 2.11 (0.42) 1.73 (NR)b 2.19 (0.66) <0.001
10 615 (30.0) Calcification, N 
(%)
No 394 64 (16.2) NR 330 (83.8) 0.177
Yes 221 27 (12.2) NR 194 (87.8)
5 298 (14.5) Tumor signal 
intensity, N (%)
Hyperintense 120 40 (33.3) NR 80 (66.6) 0.237
Iso/hypointense 178 48 (27.0) NR 130 (73.0)
12 1107 (54.0) Peritumoral 
edema, N (%)
Yes 144 47 (32.6) 24 (16.7) 73 (50.7)
No 963 145 (15.1) 365 (37.9) 453 (47.0)
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Table 4  Growth dynamics and symptom development during active monitoring stratified by baseline characteristics
AGR absolute growth rate, RGR relative growth rate, MLR multi-level regression, NA not applicable, NR not reported








OR (95% CI) MLR  Pa
Location Non-skull base 7.97/0.68 0.747 70.2/17.0 0.405 12/60 (20.0) 0.116
Skull base 5.82/2.93 28.1/17.2 5/25 (20.0)
Diameter ≥ 3.0 cm 19.7/5.91 0.004 114/24.7 0.091 15/27 (55.5) 12.16 (5.56–18.78) < 0.001
< 3.0 cm 1.56/0.46 31.4/12.7 2/58 (3.45)
Calcification No 19.0/19.0 NA 141/141 NA 1/1 (100)
Yes NR NR NR
Tumor signal intensity Hyperintense NR NA NR NA NR
Iso/hypointense NR NR NR
Peritumoral edema Yes NR NA NR NA NR
No 2.32/0.62 19.7/13.2 1/29 (3.45)
